NASDAQ: SEELSeelos Therapeutics Inc Stock
$0.34+0.00 (+0%)
Updated Apr 19, 2024
SEEL Price
$0.34
Fair Value Price
N/A
Market Cap
$4.58M
52 Week Low
$0.32
52 Week High
$49.80
P/E
-0.04x
P/B
-0.14x
P/S
3.09x
PEG
N/A
Dividend Yield
N/A
Revenue
$2.20M
Earnings
-$37.88M
Gross Margin
100%
Operating Margin
-1,716.16%
Profit Margin
-1,719.6%
Debt to Equity
-1.16
Operating Cash Flow
-$24M
Beta
1.16
Next Earnings
May 13, 2024
Ex-Dividend
N/A
Next Dividend
N/A
SEEL Overview
Seelos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of central nervous system, respiratory, and other disorders. The company's lead programs are SLS-002, an intranasal racemic ketamine for the treatment of acute suicidal ideation and behavior in patients with major depressive disorders; SLS-005, a protein stabilizer for the treatment of amyotrophic lateral sclerosis and Sanfilippo syndrome; and SLS-006, a partial dopamine agonist for the treatment of patients with Parkinson's disease (PD). Its preclinical programs include SLS-007, an anti-alpha-synuclein peptidic inhibitor to treat patients with PD; SLS-008, an orally available antagonist for chemoattractant receptor-homologous molecule for the treatment of chronic inflammation in asthma and pediatric orphan indications; SLS-004 for the treatment of PD; SLS-010, an oral histamine H3A receptor antagonist for narcolepsy and related disorders; and SLS-012, an injectable therapy for post-operative pain management. Seelos Therapeutics, Inc. was incorporated in 1987 and is headquartered in New York, New York.
Zen Score
–
Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how SEEL scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
SEEL is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
SEEL is unprofitable, so we are unable to assess its PEG ratio
PEG Value Valuation
SEEL's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
There are 30 more SEEL due diligence checks available for Premium users.
Be the first to know about important SEEL news, forecast changes, insider trades & much more!
SEEL News
Valuation
SEEL fair value
Fair Value of SEEL stock based on Discounted Cash Flow (DCF)
Price
$0.34
Fair Value
$2.17
Undervalued by
84.34%
SEEL is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
SEEL price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.04x
Industry
15.81x
Market
40.51x
SEEL price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
-0.14x
Industry
5.74x
SEEL's financial health
Profit margin
Revenue
$653.0k
Net Income
-$5.5M
Profit Margin
-835.1%
SEEL's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
SEEL's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$5.4M
Liabilities
$38.9M
Debt to equity
-1.16
SEEL's short-term liabilities ($38.93M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
SEEL's short-term assets ($5.40M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
SEEL's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
SEEL's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$1.9M
Investing
$0.0
Financing
$2.3M
SEEL's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
SEEL vs Biotech Stocks
Seelos Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.